MGNX

Company Overview — What Does MACROGENICS INC Do?

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. MACROGENICS INC (MGNX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Scott E. Koenig and employs approximately 430 people, headquartered in Rockville, Maryland. With a market capitalization of $184M, MGNX is one of the notable companies in the Healthcare sector.

MACROGENICS INC (MGNX) Stock Rating — Reduce (April 2026)

As of April 2026, MACROGENICS INC receives a Reduce rating with a composite score of 28.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MGNX ranks #2,949 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MACROGENICS INC ranks #419 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MGNX Stock Price and 52-Week Range

MACROGENICS INC (MGNX) currently trades at $3.61. The stock gained $0.17 (5.0%) in the most recent trading session. The 52-week high for MGNX is $3.54, which means the stock is currently trading 2.0% from its annual peak. The 52-week low is $0.99, putting the stock 264.8% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is MGNX Overvalued or Undervalued? — Valuation Analysis

MACROGENICS INC (MGNX) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 11.56x, compared to the Healthcare sector average of 23.63x — a discount of 51%. The price-to-book ratio stands at 3.83x, versus the sector average of 2.75x. The price-to-sales ratio is 0.97x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MGNX trades at 2.83x EV/EBITDA, versus 6.34x for the sector.

At current multiples, MACROGENICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MACROGENICS INC Profitability — ROE, Margins, and Quality Score

MACROGENICS INC (MGNX) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -7.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1.6% versus the sector average of -33.1%.

On a margin basis, MACROGENICS INC reports gross margins of 99.9%, compared to 71.5% for the sector. The operating margin is -103.5% (sector: -66.1%). Net profit margin stands at -100.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 574.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MGNX Debt, Balance Sheet, and Financial Health

MACROGENICS INC has a debt-to-equity ratio of 362.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 5.10x, indicating strong short-term liquidity. Total debt on the balance sheet is $32M. Cash and equivalents stand at $80M.

MGNX has a beta of 1.80, meaning it is more volatile than the broader market — a $10,000 investment in MGNX would be expected to move 79.6% more than the S&P 500 on any given day. The stability factor score for MACROGENICS INC is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MACROGENICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, MACROGENICS INC reported revenue of $219M and earnings per share (EPS) of $-1.18. Net income for the quarter was $-4M. Gross margin was 99.9%. Operating income came in at $-7M.

In FY 2025, MACROGENICS INC reported revenue of $150M and earnings per share (EPS) of $-1.18. Net income for the quarter was $-75M. Revenue grew -0.3% year-over-year compared to FY 2024. Operating income came in at $-73M.

In Q3 2025, MACROGENICS INC reported revenue of $73M and earnings per share (EPS) of $0.27. Net income for the quarter was $17M. Revenue grew -34.2% year-over-year compared to Q3 2024. Operating income came in at $19M.

In Q2 2025, MACROGENICS INC reported revenue of $22M and earnings per share (EPS) of $-0.57. Net income for the quarter was $-36M. Revenue grew 106.0% year-over-year compared to Q2 2024. Operating income came in at $-37M.

Over the past 8 quarters, MACROGENICS INC has demonstrated a growth trajectory, with revenue expanding from $11M to $219M. Investors analyzing MGNX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MGNX Dividend Yield and Income Analysis

MACROGENICS INC (MGNX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MGNX Momentum and Technical Analysis Profile

MACROGENICS INC (MGNX) has a momentum factor score of 55/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

MGNX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MACROGENICS INC (MGNX) ranks #419 out of 838 stocks based on the Blank Capital composite score. This places MGNX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MGNX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MGNX vs S&P 500 (SPY) comparison to assess how MACROGENICS INC stacks up against the broader market across all factor dimensions.

MGNX Next Earnings Date

No upcoming earnings date has been announced for MACROGENICS INC (MGNX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MGNX? — Investment Thesis Summary

The quantitative profile for MACROGENICS INC suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. High volatility (stability score 17/100) increases portfolio risk.

In summary, MACROGENICS INC (MGNX) earns a Reduce rating with a composite score of 28.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MGNX stock.

Related Resources for MGNX Investors

Explore more research and tools: MGNX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MGNX head-to-head with peers: MGNX vs AZN, MGNX vs SLGL, MGNX vs VMD.